AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16325694 — intervention group
Group type: COMPARATOR
Intervention: Angioplasty-first strategy
Number of subjects: 452
Study 16325694 — intervention group
Group type: COMPARATOR
Intervention: Health-related quality of life
Number of subjects: 452
Study 16325694 — intervention group
Group type: COMPARATOR
Intervention: Hospital costs
Number of subjects: 452
Study 11990204 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroblastoma cell bioassay for ciguatoxins
Number of subjects: 111
Study 11990204 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic negative controls
Number of subjects: 111
Study 11990204 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic negative controls
Number of subjects: 111
Study 11990204 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential ciguatoxic patients
Number of subjects: 111
Study 9485250 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugal vortex pump
Number of subjects: 41
Study 9485250 — intervention group
Group type: COMPARATOR
Intervention: Standard roller pump
Number of subjects: 41
Study 7715941 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient cognitive-behavioural therapy (CBT) with amitriptyline (AMI)
Number of subjects: 0
Study 7715941 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy with amitriptyline (AMI)
Number of subjects: 0
Study 2611615 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) (Roferon A, Roche, Basle, Switzerland) 18 x 10(6) u i.m. 3 times/week
Number of subjects: 49
Study 2611615 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IFN with vinblastine (0.1 mg/kg every third week)
Number of subjects: 49
Study 2611615 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN)
Number of subjects: 49
Study 299841 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenorenal anastomosis
Number of subjects: 225
Study 299841 — intervention group
Group type: COMPARATOR
Intervention: Portocaval anastomosis
Number of subjects: 225
Study 299841 — intervention group
Group type: COMPARATOR
Intervention: Mesentericocaval anastomosis
Number of subjects: 225
Study 299841 — intervention group
Group type: COMPARATOR
Intervention: Palliative operations
Number of subjects: 225
Study 299841 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapeutic approaches
Number of subjects: 225
Study 30945426 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential education programme (3 lessons)
Number of subjects: 120
Study 30945426 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study 28347975 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily text message reminders for a 30‐day intervention phase following hospitalization.
Number of subjects: 40
Study 26182956 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-school restorative approach to address bullying and aggression
Number of subjects: 1144
Study 26182956 — intervention group
Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 1144
Study 24138537 — intervention group
Group type: COMPARATOR
Intervention: LPV/r 400/100 mg
Number of subjects: 63
Study 24138537 — intervention group
Group type: EXPERIMENTAL
Intervention: LPV/r 600/150 mg
Number of subjects: 63
Study 21290136 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic inguinal herniotomy
Number of subjects: 2699
Study 19496959 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 150-225 mg
Number of subjects: 18
Study 19496959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 16455387 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with allergic rhinitis
Number of subjects: 26
Study 16455387 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 14669181 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training with partial body-weight support (TT-BWS)
Number of subjects: 80
Study 11269898 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 19
Study 11269898 — intervention group
Group type: COMPARATOR
Intervention: Control (drugs only)
Number of subjects: 19
Study 8985765 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin nasal ointment
Number of subjects: 226
Study 8985765 — intervention group
Group type: COMPARATOR
Intervention: Control group (historic control)
Number of subjects: 226
Study 1456861 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEP lecture + generic chart reminders of NCEP guidelines
Number of subjects: 240
Study 1456861 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEP lecture + timely patient-specific feedback
Number of subjects: 240
Study 1456861 — intervention group
Group type: COMPARATOR
Intervention: PCEP lecture only (Control group)
Number of subjects: 240
Study 3969035 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking intervention programme administered by general practitioners
Number of subjects: 0
Study 3969035 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 30473185 — intervention group
Group type: EXPERIMENTAL
Intervention: ETVAX with dmLT adjuvant
Number of subjects: 45
Study 30473185 — intervention group
Group type: EXPERIMENTAL
Intervention: ETVAX without dmLT adjuvant
Number of subjects: 45
Study 30473185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 30879831 — intervention group
Group type: EXPERIMENTAL
Intervention: XEN® Gel Stent as a stand-alone procedure
Number of subjects: 777
Study 30879831 — intervention group
Group type: EXPERIMENTAL
Intervention: XEN® Gel Stent in combined surgery
Number of subjects: 777
Study 30879831 — intervention group
Group type: COMPARATOR
Intervention: Complications
Number of subjects: 777
Study 28406791 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered assessment process
Number of subjects: 0
Study 28406791 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement of patient and physician stakeholders
Number of subjects: 0
Study 25933728 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal RBC transfusion strategy (Hb < 11.3 g/dL, 7 mmol/L)
Number of subjects: 157
Study 25933728 — intervention group
Group type: COMPARATOR
Intervention: Restrictive RBC transfusion strategy (Hb < 9.7 g/dL, 6 mmol/L)
Number of subjects: 157
Study 25933728 — intervention group
Group type: EXPERIMENTAL
Intervention: Both strategies
Number of subjects: 157
Study 23903529 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum protein concentrate (CPC) supplementation (10 g/day)
Number of subjects: 10
Study 23903529 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 g whey protein concentrate/day)
Number of subjects: 10
Study 22077684 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and dental education in one session for children and parents
Number of subjects: 160
Study 22077684 — intervention group
Group type: COMPARATOR
Intervention: Control group (no instructions)
Number of subjects: 160
Study 19936370 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiNose's novel delivery device (Opt‐FP) 400 microg twice daily for 12 weeks
Number of subjects: 109
Study 17956212 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclod (diclofenac sodium)
Number of subjects: 63
Study 17956212 — intervention group
Group type: COMPARATOR
Intervention: Rinderon (betamethasone phosphate)
Number of subjects: 63
Study 13680266 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant follicle‐stimulating hormone (rFSH) + human menopausal gonadotrophin (HMG)
Number of subjects: 0
Study 13680266 — intervention group
Group type: COMPARATOR
Intervention: recombinant follicle‐stimulating hormone (rFSH) alone
Number of subjects: 0
Study 13680266 — intervention group
Group type: EXPERIMENTAL
Intervention: short protocol with luteinizing hormone (LH) added from the beginning
Number of subjects: 0
Study 13680266 — intervention group
Group type: COMPARATOR
Intervention: high day 3 serum FSH concentrations (>9 mIU/ml)
Number of subjects: 0
Study 11273950 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (100 mg IV during surgery and 8 hours later)
Number of subjects: 214
Study 11273950 — intervention group
Group type: COMPARATOR
Intervention: Control (propacetamol alone)
Number of subjects: 214
Study 9228494 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) patch therapy
Number of subjects: 0
Study 9228494 — intervention group
Group type: COMPARATOR
Intervention: Control group (normotensive patients)
Number of subjects: 0
Study 8427034 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza subunit vaccine (0, 10, 20, and 60 micrograms)
Number of subjects: 0
Study 3036023 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalidixic acid (2%) applied twice daily under occlusion
Number of subjects: 7
Study 3036023 — intervention group
Group type: EXPERIMENTAL
Intervention: Novobiocin (2% or 5%) applied twice daily under occlusion
Number of subjects: 7
Study 3036023 — intervention group
Group type: COMPARATOR
Intervention: Methylcellulose alone (control)
Number of subjects: 7
Study 28295686 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 26
Study 28295686 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 26
Study 27240787 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir group (oral ritonavir-boosted lopinavir 100 mg ritonavir, 400 mg lopinavir plus 400 mg raltegravir twice a day)
Number of subjects: 515
Study 27240787 — intervention group
Group type: COMPARATOR
Intervention: NRTI group (ritonavir-boosted lopinavir plus two or three NRTIs)
Number of subjects: 515
Study 27240787 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir group
Number of subjects: 515
Study 27240787 — intervention group
Group type: COMPARATOR
Intervention: NRTI group
Number of subjects: 515
Study 27240787 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 515
Study 24912498 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA85A
Number of subjects: 0
Study 24912498 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Candin)
Number of subjects: 0
Study 23252844 — intervention group
Group type: EXPERIMENTAL
Intervention: ICF-based patient education programme
Number of subjects: 213
Study 23252844 — intervention group
Group type: COMPARATOR
Intervention: Attention-placebo control intervention
Number of subjects: 213
Study 21651955 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% TiO(2) nanoparticles
Number of subjects: 0
Study 21651955 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% TiO(2) nanoparticles
Number of subjects: 0
Study 21651955 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% TiO(2) nanoparticles
Number of subjects: 0
Study 21651955 — intervention group
Group type: EXPERIMENTAL
Intervention: TiO(2) nanoparticles (3%, 5%, 7%)
Number of subjects: 0
Study 21651955 — intervention group
Group type: COMPARATOR
Intervention: Unmodified GI
Number of subjects: 0
Study 18266660 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxysmal AF
Number of subjects: 7329
Study 18266660 — intervention group
Group type: COMPARATOR
Intervention: Persistent AF
Number of subjects: 7329
Study 18266660 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk paroxysmal AF (>=2 stroke risk factors)
Number of subjects: 7329
Study 18266660 — intervention group
Group type: COMPARATOR
Intervention: High risk persistent AF (>=2 stroke risk factors)
Number of subjects: 7329
Study 18266660 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly paroxysmal AF
Number of subjects: 7329
Study 18266660 — intervention group
Group type: COMPARATOR
Intervention: Elderly persistent AF
Number of subjects: 7329
Study 18266660 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonist (VKA)‐naive paroxysmal AF
Number of subjects: 7329
Study 18266660 — intervention group
Group type: COMPARATOR
Intervention: Previous VKA takers with paroxysmal AF
Number of subjects: 7329
Study 17064200 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention group
Number of subjects: 463
Study 17064200 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control) group
Number of subjects: 463
Study 17064200 — intervention group
Group type: COMPARATOR
Intervention: Pharmacist intervention group and Usual care (control) group
Number of subjects: 463
Study 12832367 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin antagonist (atosiban)
Number of subjects: 10
Study 12832367 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 10
Study 11167965 — intervention group
Group type: EXPERIMENTAL
Intervention: Exorex (1% coal tar with esterified essential fatty acids)
Number of subjects: 20
Study 11167965 — intervention group
Group type: COMPARATOR
Intervention: Coal tar control (Exorex without the essential fatty acid component)
Number of subjects: 20
Study 11167965 — intervention group
Group type: COMPARATOR
Intervention: Exorex and Coal tar control
Number of subjects: 20
Study 9327820 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Reach Test (FRT)
Number of subjects: 20
Study 9327820 — intervention group
Group type: COMPARATOR
Intervention: Postural sway measures on the Balance System
Number of subjects: 20
Study 8447842 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of 2 mg folic acid
Number of subjects: 15
Study 8447842 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of 2 mg folic acid
Number of subjects: 15
Study 2447860 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral intravenous crystalloid solution and routine ward observations
Number of subjects: 100
Study 2447860 — intervention group
Group type: COMPARATOR
Intervention: Peritoneal lavage as adjunctive therapy
Number of subjects: 100
Study 29710380 — intervention group
Group type: EXPERIMENTAL
Intervention: TNA + multivitamin (Group A)
Number of subjects: 30
Study 29710380 — intervention group
Group type: COMPARATOR
Intervention: TNA + normal saline (Group B)
Number of subjects: 30
Study 27833922 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay Health Trainer (LHT) intervention
Number of subjects: 76
Study 27833922 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 76
Study 24002913 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 100 mg
Number of subjects: 213
Study 24002913 — intervention group
Group type: COMPARATOR
Intervention: Control (no antiplatelet agents)
Number of subjects: 213
Study 23189232 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy milk
Number of subjects: 24
Study 23189232 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk
Number of subjects: 24
Study 15881644 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex therapy (CT) plus a composition of replaceable amino acids (CRAA) sublingually and orally
Number of subjects: 129
Study 15881644 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex therapy (CT) plus melatonin in doses of 3 and 6 mg
Number of subjects: 129
Study 15881644 — intervention group
Group type: COMPARATOR
Intervention: Complex therapy (CT) only
Number of subjects: 129
Study 15881644 — intervention group
Group type: COMPARATOR
Intervention: Complex therapy (CT) plus placebo
Number of subjects: 129
Study 12882479 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (150 min weekly of moderate intensity physical activity, such as brisk walking)
Number of subjects: 0
Study 9779029 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (lower dose 1.0 mg/kg)
Number of subjects: 0
Study 9779029 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 0
Study 9779029 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 0
Study 9779029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8681499 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolrestat 200 mg orally once daily for six months
Number of subjects: 74
Study 8681499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 2796443 — intervention group
Group type: EXPERIMENTAL
Intervention: mecillinam (1.200 mg/day p.o.) for 5 days
Number of subjects: 134
Study 2796443 — intervention group
Group type: EXPERIMENTAL
Intervention: co‐trimoxazole (1.600 mg/day p.o.) for 5 days
Number of subjects: 134
Study 2796443 — intervention group
Group type: COMPARATOR
Intervention: diet only
Number of subjects: 134
Study 682818 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous lateral sphincterotomy
Number of subjects: 0
Study 682818 — intervention group
Group type: COMPARATOR
Intervention: Digital dilatation and sphincterotomy
Number of subjects: 0
Study 29461134 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported methamphetamine use in the past 3 days
Number of subjects: 90
Study 29461134 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported methamphetamine use over an extended recall period of 1 month
Number of subjects: 90
Study 27130038 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial botulinum Toxin‐A (BTX) injections
Number of subjects: 0
Study 27130038 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 25002389 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic ex vivo allograft blood perfusion using an organ care system (OCS)
Number of subjects: 159
Study 25002389 — intervention group
Group type: COMPARATOR
Intervention: Cold static storage with histidine-tryptophan-ketoglutarate solution (Custodiol)
Number of subjects: 159
Study 22190554 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic plus simulation-based training
Number of subjects: 54
Study 22190554 — intervention group
Group type: COMPARATOR
Intervention: Didactic training alone
Number of subjects: 54
Study 20568303 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon (PEG‐IFN) alfa‐2b at 1.5 microg/kg/week with ribavirin (RBV) at 800 to 1400 mg/day
Number of subjects: 3070
Study 20568303 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon (PEG‐IFN) alfa‐2b at 1.0 microg/kg/week with RBV at 800 to 1400 mg/day
Number of subjects: 3070
Study 20568303 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon (PEG‐IFN) alfa‐2a at 180 microg/week with RBV at 1000 to 1200 mg/day
Number of subjects: 3070
Study 20568303 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin pretreatment
Number of subjects: 3070
Study 20568303 — intervention group
Group type: COMPARATOR
Intervention: No statin pretreatment
Number of subjects: 3070
Study 20568303 — intervention group
Group type: COMPARATOR
Intervention: Normal LDL and HDL levels
Number of subjects: 3070
Study 18502512 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 1052
Study 18502512 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 1052
Study 16105990 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents
Number of subjects: 250
Study 16105990 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stents
Number of subjects: 250
Study 11832869 — intervention group
Group type: EXPERIMENTAL
Intervention: Snowshoe training
Number of subjects: 17
Study 11832869 — intervention group
Group type: COMPARATOR
Intervention: Running training
Number of subjects: 17
Study 10081520 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg daily
Number of subjects: 29
Study 10081520 — intervention group
Group type: COMPARATOR
Intervention: Folic acid 1 mg daily
Number of subjects: 29
Study 10081520 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine 4 g daily
Number of subjects: 29
Study 7751897 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) 100 mg/m2 intravenously on day 1 and Fluorouracil (FU) 5,000 mg/m2 over a 120-hour continuous infusion
Number of subjects: 95
Study 7751897 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin (CBDCA) 400 mg/m2 over a 24-hour continuous infusion on day 1 and Fluorouracil (FU) with the same schedule
Number of subjects: 95
Study 2309606 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 15
Study 2309606 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 15
Study 2309606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30781908 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-Uterine Contraceptive Devices (IUCD)
Number of subjects: 40
Study 30781908 — intervention group
Group type: COMPARATOR
Intervention: Control (without IUCD)
Number of subjects: 40
Study 31992269 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Compassion Online (SCO) program
Number of subjects: 0
Study 31992269 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study 31133629 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck pain
Number of subjects: 1221
Study 31133629 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulders pain
Number of subjects: 1221
Study 31133629 — intervention group
Group type: EXPERIMENTAL
Intervention: Low back pain
Number of subjects: 1221
Study 31133629 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug consumption for MSP
Number of subjects: 1221
Study 31133629 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep disturbance
Number of subjects: 1221
Study 31133629 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive behaviors
Number of subjects: 1221
Study 28219458 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy - Cognitive Only (CPT)
Number of subjects: 8
Study 25755212 — intervention group
Group type: EXPERIMENTAL
Intervention: ivacaftor
Number of subjects: 209
Study 25755212 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 209
Study 23122918 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS of the somatosensory cortex for 5 consecutive days
Number of subjects: 0
Study 23122918 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0
Study 23122918 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 0
Study 21059664 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Nottingham Extended ADL Scale
Number of subjects: 70
Study 21059664 — intervention group
Group type: EXPERIMENTAL
Intervention: Frenchay Activities Index
Number of subjects: 70
Study 18836986 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing thickness of carotid artery intima-media thickness (CIMT)
Number of subjects: 504
Study 18836986 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery calcium (CAC)
Number of subjects: 504